[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Last updated 17.09.2018
Commission awarded on 15.06.2018 by the Federal Joint Committee (G-BA).
Treatment-naive adults with advanced (unresectable or metastatic) melanoma with BRAF V600 WT tumour
Due to disadvantages in health-related quality of life and side effects, indication of lesser benefit in comparison with the appropriate comparator therapy (nivolomab alone)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.